The study describes how specialized regions known as macrophage niches can influence the biological state of non-small cell lung cancer stem cells. A niche is more than a physical location inside a tumor. It is a dynamic microenvironment made up of immune cells, connective-tissue cells, blood vessels, signaling molecules and extracellular matrix components. Together, these elements provide chemical and mechanical instructions that can alter how cancer cells grow, move, survive and respond to treatment. In this setting, macrophages appear to help push tumor cells into flexible states associated with dormancy, epithelial–mesenchymal transition and drug resistance.

Cancer stem cells are a small but important population within many tumors. Unlike the majority of cancer cells, they can self-renew and generate different tumor cell types, allowing a malignancy to rebuild itself after treatment. Their ability to remain alive in a slow-growing or non-dividing state is particularly significant. Dormant cells may escape therapies designed to kill rapidly dividing cells, then become active again months or years later. This biological “pause” can help explain why a patient may initially respond well to treatment but later experience relapse.

The research links macrophage-rich environments to this dormant behavior. Macrophages are part of the innate immune system and normally remove damaged cells, coordinate inflammation and support tissue repair. Tumors can reshape these cells through chemical signals, creating tumor-associated macrophages that often suppress immune attacks and promote tissue remodeling. Within lung tumors, these macrophages may release growth factors, cytokines and other signaling molecules that activate survival programs in cancer stem cells. Instead of simply stimulating proliferation, the signals can encourage cells to enter a protected, low-activity state.

A central concept in the study is tumor plasticity, the ability of cancer cells to change their characteristics without necessarily acquiring new genetic mutations. This flexibility allows a tumor cell to shift between states depending on environmental pressure. A cell may become highly invasive during one phase, dormant during another and actively dividing when conditions improve. Such changes are controlled through networks involving transcription factors, cell-surface receptors, metabolic pathways and epigenetic modifications, which alter gene activity without changing the underlying DNA sequence.

The researchers also connect macrophage niches with epithelial–mesenchymal transition, commonly known as EMT. During EMT, cells lose features associated with epithelial tissue, such as strong cell-to-cell adhesion, and acquire mesenchymal traits that increase mobility and invasiveness. In cancer, EMT can help tumor cells detach from the primary mass, migrate through surrounding tissue and enter the bloodstream. It is also associated with stem-like properties and resistance to several forms of therapy. The study suggests that macrophage-derived signals may help lung cancer stem cells move along this spectrum, linking dormancy and metastatic potential rather than treating them as separate phenomena.

Chemoresistance is another major consequence of this cellular flexibility. Many chemotherapy drugs are most effective against cells that are actively replicating or depend heavily on particular metabolic pathways. Dormant cancer stem cells may avoid these vulnerabilities by reducing proliferation and changing their metabolism. EMT-associated cells can also increase drug-export mechanisms, strengthen DNA-damage responses and activate anti-apoptotic pathways that prevent programmed cell death. If macrophage niches maintain these protective states, they could act as local shelters where cancer cells survive treatment and later repopulate the tumor.

These findings may help explain why targeting tumor cells alone is often insufficient. A therapy can eliminate a large fraction of malignant cells while leaving behind a smaller population protected by its microenvironment. The results point toward combination strategies that attack both cancer stem cells and the macrophage signals supporting them. Potential approaches could include therapies that reprogram tumor-associated macrophages, block specific communication pathways between macrophages and cancer cells, or force dormant cells into a vulnerable state before conventional treatment. Such strategies remain an area of investigation and would require careful testing because macrophages also perform essential functions in normal immunity and tissue repair.

The study does not suggest that every macrophage in every lung tumor behaves identically, nor that dormancy, EMT and drug resistance are controlled by a single mechanism. Tumors are highly diverse, and the behavior of a macrophage niche can depend on its location, molecular composition and interaction with other immune and stromal cells. Translating these observations into patient treatments will require determining which signaling pathways are most important in individual tumors and identifying reliable biomarkers that reveal when cancer stem cells are being protected by their surroundings. Even so, the work reinforces a growing principle in cancer biology: treatment resistance is not solely a property of tumor cells, but can emerge from an ongoing conversation between malignant cells and the ecosystem around them.

Subject of Research: The role of macrophage niches and tumor plasticity in regulating dormancy, epithelial–mesenchymal transition and chemotherapy resistance in non-small cell lung cancer stem cells.

Article Title: Tumor plasticity in macrophage niches promotes dormancy, EMT and chemoresistance of non-small cell lung cancer stem cells.

Article References: Zeuner, A., Sette, G., Rossi, S. et al. “Tumor plasticity in macrophage niches promotes dormancy, EMT and chemoresistance of non-small cell lung cancer stem cells.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03261-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03261-1

Keywords: non-small cell lung cancer, cancer stem cells, macrophages, tumor microenvironment, tumor plasticity, dormancy, epithelial–mesenchymal transition, EMT, chemoresistance, cancer relapse

Acetate, a simple two-carbon molecule, has garnered considerable interest due to its integral role in oncogenic metabolism. It serves as a substrate for the synthesis of acetyl-coenzyme A (acetyl-CoA), a key metabolic intermediate intricately involved in the catabolism of glucose, lipids, and amino acids. Beyond its metabolic duties, acetyl-CoA functions as a crucial signaling molecule, facilitating lysine acetylation on histones and other proteins, thereby influencing gene expression and cellular behavior. Elevated acetyl-CoA levels have been consistently linked with aggressive metastatic phenotypes in various cancers, emphasizing the need to understand acetate’s origins within tumor niches.

Previous investigations have noted a perplexing discrepancy: acetate concentrations in the bloodstream are significantly lower than those found within cancerous tissues. This disparity suggested that acetate production was localized within the tumor microenvironment itself. Yet, the precise cellular sources and pathways responsible remained elusive until the recent study conducted by Dr. LU Ming and colleagues from the Shanghai Institute of Nutrition and Health, in partnership with Huashan Hospital at Fudan University.

Their research illuminates a sophisticated metabolic crosstalk between HCC cells and TAMs, whereby the carcinoma cells secrete lactate—a metabolic byproduct abundant in tumors—that acts as a potent signaling molecule. This lactate engages TAMs, enhancing intracellular reactive oxygen species (ROS) levels and triggering lipid peroxidation. The oxidative degradation of lipids generates aldehyde molecules, which are subsequently metabolized by aldehyde dehydrogenase 2 (ALDH2) expressed in TAMs. This sequential activation of the lipid peroxidation–ALDH2 pathway culminates in the production and release of acetate by TAMs into the tumor milieu.

The secreted acetate does not remain idle; HCC cells avidly uptake this metabolite and convert it into acetyl-CoA. This metabolic fuel supports histone H3 acetylation, a post-translational modification that amplifies gene transcription programs associated with the epithelial-mesenchymal transition (EMT). EMT is a hallmark of cancer metastasis, enabling tumor cells to acquire invasive and migratory capabilities critical for dissemination from the primary site to distant organs.

Experimental models underscore the centrality of TAM-derived acetate in promoting metastasis. In an orthotopic mouse model of HCC, selective depletion of TAMs drastically reduced intracellular acetate concentrations within tumor cells and significantly impaired lung metastasis development. Complementary in vitro studies confirmed that pharmacological inhibition of ALDH2 or blockade of lipid peroxidation in TAMs hindered acetate production, subsequently attenuating the migratory behavior of HCC cells.

Genetic approaches further solidified this mechanistic insight. Ablation of the Aldh2 gene specifically in TAMs not only curtailed acetate generation but also yielded a profound suppression of metastatic colonization in the lungs. Collectively, these findings position the lipid peroxidation–ALDH2 axis in TAMs as a mechanistic keystone critical for sustaining acetate reservoirs that potentiate HCC progression.

The elucidation of lactate’s upstream role in this metabolic interplay expands the understanding of tumor-stroma communication. Lactate, long considered a metabolic waste product, is increasingly recognized as a signaling metabolite that remodels immune cells and stromal elements to favor tumor growth. Here, its engagement of TAMs potentiates ROS-mediated lipid peroxidation events, coupling metabolic dysfunction with epigenetic reprogramming downstream in cancer cells.

This study provides a compelling conceptual advance by revealing how the tumor microenvironment’s metabolic plasticity can be exploited by HCC cells to foster metastasis. The identification of TAMs as acetate reservoirs via the lipid peroxidation–ALDH2 pathway not only clarifies a previously obscure aspect of tumor metabolism but also presents a tangible therapeutic avenue. Targeting this axis may disrupt the supply of acetate necessary for acetyl-CoA–dependent epigenetic modifications that empower malignant traits, offering a promising strategy to inhibit liver cancer dissemination.

Beyond its mechanistic insights, this research underscores the importance of metabolic symbiosis in cancer and the complex interplay between immune cells and tumor cells. As cancer therapies increasingly incorporate metabolic modulation, deciphering these intercellular metabolic networks will be crucial for designing efficacious interventions. The work spearheaded by Dr. LU Ming’s group lays a robust foundation for future explorations into targeting TAMs’ metabolic functions to thwart HCC metastasis.

This endeavor was supported by formidable national funding bodies, including the National Key R&D Program of China and the National Natural Science Foundation of China, reflecting the high scientific priority accorded to advancing understanding and treatment of liver cancer.

As hepatocellular carcinoma continues to pose a significant global health challenge with limited treatment options for metastatic disease, the present findings offer fresh hope. Interfering with the acetate reservoir function of TAMs could transform the therapeutic landscape and improve outcomes for patients grappling with this deadly malignancy. The integration of metabolic insights and immunological context provides a timely paradigm for future cancer research and precision medicine strategies.

Subject of Research: Not applicable
Article Title: Tumour-associated macrophages serve as an acetate reservoir to drive hepatocellular carcinoma metastasis
News Publication Date: 20-Oct-2025
Web References: https://doi.org/10.1038/s42255-025-01393-9
Image Credits: LU Ming’s group
Keywords: Cancer cells, Hepatocellular carcinoma, Metastasis, Liver tumors